| abstract |
Human RelA-associated inhibitor (RAI) comprising 351 aminonacid, process for producing it, cDNA encoding it, fragment capable ofnhybridizing selectively to the cDNA sequence, plasmid for expressionnand duplication comprising the cDNA, host cell transformed with thenplasmid, antibody against the polypeptide, pharmaceuticalncomposition comprising the polypeptide or the antibody against itnand method for diagnosis of diseases using the antibody against thenRAI. n RAI of the invention is capable of binding to p65, which is ansubmit of transcription factor NFκB, therefore, it is thought to benuseful for treatment and/or prevention of various diseases. |